Trial Profile
Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Pavinetant (Primary)
- Indications Hot flashes
- Focus Proof of concept; Therapeutic Use
- 08 Nov 2017 Status changed from active, no longer recruiting to discontinued, as reported in a Millendo Therapeutics media release.
- 15 May 2017 According to a Millendo Therapeutics media release, data from this study will be presented at the 19th European Congress of Endocrinology (ECE).
- 03 Apr 2017 Results published in a Millendo Therapeutics media release.